Ariel’s initial focus is pancreatic diseases including pancreatitis, diabetes and pancreatic cancer. PancreasDx® is Ariel’s proprietary multi-gene DNA sequencing panel that identifies combinations of genetic mechanisms likely driving the disease.
A comprehensive interpretation of the genetic data is provided in the context of each patient’s current symptoms, biomarkers and health history. Ariel’s technologies are leading the paradigm shift from single-gene (Mendelian) genetics to complex gene-to-gene interactions and the integration of lifestyle and environmental factors to provide a more comprehensive view of disease trajectory and precise therapeutic options.
ADVANCE®, Ariel’s genetic segmentation platform, enables patient-specific treatment decisions to be based on the most advanced insights into systems biology, evidence-based medicine, genetic linkages and domain expertise. This has created a novel and scalable solution that enables clinicians and researchers to identify and diagnose the underlying biological causes of symptoms and move beyond diagnosing and treating the general symptoms.
Ariel strives to go beyond genetics, helping clinicians make more informed decisions about the treatment of complex chronic diseases. Our team of professionals is dedicated to removing the complexity from genetic testing results, giving you and your team actionable information to prevent, mitigate or reverse disease progression.